aTyr PharmaATYR +1.74%14 EBIT per Share is $-0.77 as of Mar. 2026. GuruFocus rates ATYR with a GF Score™ of 14/100 and a GF Value™ of $0.46 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 1,181 Biotechnology companies, aTyr Pharma ranks better than 56.05% on this metric.
aTyr Pharma's EBIT per Share for the
three
months ended in Mar. 2026 was $-0.12.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.77.
During the past 3 years, the average EBIT per Share Growth Rate was 20.00% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 16.10% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 36.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for aTyr Pharma's EBIT per Share or its related term are showing as below:
ATYR'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -8.1 Med: 24.3 Max: 59.2
Current: 20
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of aTyr Pharma was 59.20% per year. The lowest was -8.10% per year. And the median was 24.30% per year.
ATYR's 3-Year EBIT Growth Rate is ranked better than 56.05% of 1181
companies
in the Biotechnology industry
Industry Median: 15.5
vs ATYR: 20.00
aTyr Pharma's EBIT for the
three
months ended in Mar. 2026 was $-11.44 Mil.
aTyr Pharma (NAS:ATYR) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
aTyr Pharma EBIT per Share Related Terms
aTyr Pharma EBIT per Share Historical Data
* Premium members only.
The historical data trend for aTyr Pharma's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.77
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
aTyr Pharma (ATYR) has a EBIT per Share of $-0.77 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on aTyr Pharma and its competitors. According to the industry distribution chart, aTyr Pharma ranks #519 out of 1181 companies in the Biotechnology industry, placing it in the top 43.9%.
Is aTyr Pharma's EBIT per Share too high?
aTyr Pharma's current EBIT per Share is $-0.77. Based on the distribution chart, aTyr Pharma ranks #519 out of 1181 companies in the Biotechnology industry, which is above the industry midpoint. Overall, aTyr Pharma has a GF Score™ of 14/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does aTyr Pharma's EBIT per Share compare to DWTX and CNTX?
According to the Biotechnology industry distribution chart, aTyr Pharma ranks #519 out of 1181 companies for EBIT per Share. This puts aTyr Pharma in the upper half of its industry. The industry median EBIT per Share is 15.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.50, based on 1,181 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on aTyr Pharma and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. aTyr Pharma's current EBIT per Share is $-0.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is aTyr Pharma stock overvalued right now?
Based on GuruFocus' analysis, aTyr Pharma (ATYR) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.46, compared to a current price of $0.58 — trading 26.1% above its estimated fair value. The current EBIT per Share is $-0.77. aTyr Pharma's overall GF Score™ is 14/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For aTyr Pharma (ATYR), the current EBIT per Share is $-0.77 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is aTyr Pharma (ATYR) Overvalued in 2026?
Based on GuruFocus' analysis, aTyr Pharma stock appears to be overvalued.
The current stock price of $0.58 is trading 26.1% above its estimated GF Value™ of $0.46.
GuruFocus considers aTyr Pharma to be Modestly Overvalued.
Key valuation signals for ATYR:
EBIT per Share: $-0.77
GF Value™: $0.46 vs. price of $0.58 (26.1% above fair value)
No single metric tells the full story. See the ATYR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).
14GF Score
Get the complete analysis for ATYR
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ATYR has been successfully added to your 
